Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19 by Van Damme, Karel et al.
Frontiers in Immunology | www.frontiersin.
Edited by:
Andrew R. Gennery,










†These authors share first authorship
Specialty section:
This article was submitted to
Primary Immunodeficiencies,
a section of the journal
Frontiers in Immunology
Received: 20 August 2020
Accepted: 26 October 2020
Published: 20 November 2020
Citation:
Van Damme KFA, Tavernier S,
Van Roy N, De Leeuw E,
Declercq J, Bosteels C, Maes B,
De Bruyne M, Bogaert D,
Bosteels B, Hoste L, Naesens L,
Maes P, Grifoni A, Weiskopf D,
Sette A, Depuydt P, Van Braeckel E,
Haerynck F and Lambrecht BN (2020)
Case Report: Convalescent Plasma, a
Targeted Therapy for Patients with




published: 20 November 2020
doi: 10.3389/fimmu.2020.596761Case Report: Convalescent
Plasma, a Targeted Therapy for
Patients with CVID and Severe
COVID-19
Karel F. A. Van Damme1,2†, Simon Tavernier1,3†, Nele Van Roy1, Elisabeth De Leeuw1,2,
Jozefien Declercq1,2, Cédric Bosteels1,2, Bastiaan Maes1,2, Marieke De Bruyne4,
Delfien Bogaert1,5, Victor Bosteels1,6, Levi Hoste1,5, Leslie Naesens1,5, Piet Maes7,
Alba Grifoni8, Daniela Weiskopf8, Alessandro Sette8,9, Pieter Depuydt1,10,
Eva Van Braeckel1,11, Filomeen Haerynck1,5 and Bart N. Lambrecht1,2,11,12*
1 Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, 2 Laboratory of Immunoregulation and
Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium, 3 Unit of Molecular Signal Transduction
in Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium, 4 Center for Medical Genetics, Ghent
University Hospital, Ghent, Belgium, 5 Primary Immunodeficiency Research Lab, Jeffrey Modell Diagnosis and Research
Center, Ghent University Hospital, Ghent, Belgium, 6 Laboratory of ER Stress and Inflammation, VIB-UGent Center for
Inflammation Research, Ghent, Belgium, 7 Department of Microbiology, Immunology, and Transplantation, Rega Institute for
Medical Research, Division of Clinical and Epidemiological Virology, KU Leuven, Leuven, Belgium, 8 Center for Infectious
Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States, 9 Department of Medicine,
Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), CA, United States,
10 Department of Intensive Care, Ghent University Hospital, Ghent, Belgium, 11 Department of Respiratory Medicine, Ghent
University Hospital, Ghent, Belgium, 12 Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, Netherlands
The disease course of COVID-19 in patients with immunodeficiencies is unclear, as well as
the optimal therapeutic strategy. We report a case of a 37-year old male with common
variable immunodeficiency disorder and a severe SARS-CoV-2 infection. After
administration of convalescent plasma, the patient’s condition improved rapidly.
Despite clinical recovery, viral RNA remained detectable up to 60 days after onset of
symptoms. We propose that convalescent plasma might be considered as a treatment
option in patients with CVID and severe COVID-19. In addition, in patients with
immunodeficiencies, a different clinical course is possible, with prolonged viral shedding.
Keywords: convalescent plasma, COVID-19, common variable immunodeficiency disorders, immunodeficiencies,
case reportINTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), was first identified in Wuhan, China in December 2019 and has since evolved into a
pandemic. The majority of COVID-19 patients experience mild symptoms and recover
spontaneously. In some patients however, infection may lead to severe hypoxemia, acute
respiratory distress syndrome (ARDS) and death.
Next to antiviral and immunomodulatory agents, convalescent plasma might be a therapeutic
option, as it has previously been used for several emerging infectious diseases, including SARS-CoVorg November 2020 | Volume 11 | Article 5967611
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COVID-19, two randomized trials with convalescent plasma
failed to demonstrate benefit so far, although both were
stopped early due to insufficient patient enrolment and the
presence of anti-SARS-CoV-2 antibodies, respectively (3, 4).
COVID-19 patients with primary and secondary
immunodeficiencies might be ideal candidates for passive
immunization, since a proportion of these patients will be unable
to mount adequate antiviral responses to SARS-CoV-2. Only a few
descriptions of patients with humoral immunodeficiencies and
COVID-19 infection have been published (5–8). None of these
patients received convalescent plasma.CASE DESCRIPTION
We report a case of life-threatening COVID-19 in a 37-year-old
man with a marked decrease in all immunoglobulin classes and a
Bruton-like early B cell development block with nearly absent B
cells. The patient was born in 1983 and is the child of Turkish
parents. From childhood on, this patient suffered from recurring
upper and lower respiratory tract infections. At adult age, the
patient developed mild chronic lung disease characterized by
bronchiectatic changes (for a detailed clinical and immunological
examination, see Supplementary Table 1). The familial pedigree
did not reveal a Mendelian inheritance of immunodeficiency and
there was no reported consanguinity. Whole exome sequencing was
performed and analysis of known primary immunodeficiency genes
failed to detect disease causing variants (see Supplementary Table
2). Common variable immunodeficiency (CVID) was diagnosed
and the patient has been receiving weekly subcutaneous injections
with immunoglobulins (Hizentra) for 13 years, which led to a
significant reduction of severe respiratory tract infections.
At the first peak of the COVID-19 epidemic in Belgium, the
patient presented at the emergency department with fever, anorexia
and a non-productive cough for 8 days (see Figure 1). Family
members reported similar symptoms. Shortness of breath had
developed 2 days prior to presentation and physical examination
revealed inspiratory crepitations over both lungs. The initial work-
up showed elevated CRP, ferritin, lactate dehydrogenase and D-
dimer levels, without detectable eosinophils and a normal
lymphocyte count (see Supplementary Table 3). Arterial blood
gas showedmild hypoxemic respiratory failure, corresponding to anFIGURE 1 | Timeline of the hospitalisation.
Frontiers in Immunology | www.frontiersin.org 2Alveolar-arterial (Aa)-gradient of 34,4 mmHg (expected gradient of
13.3 mm Hg). An initial chest CT scan revealed bilateral ground-
glass opacities (see Figure 2). Given the ongoing pandemic and a
typical presentation, COVID-19 was suspected and his
nasopharyngeal swab tested positive for SARS-CoV-2.
The patient was admitted to the COVID-19 ward and empirical
treatment with antibiotics and hydroxychloroquine was initiated
according to the then applicable guidelines. He was included in a
clinical trial and randomized to the standard of care arm (9). After 3
days of hospitalization, the patient had unremitting fever and his
respiratory status progressively deteriorated. On day 6 of
hospitalization, the patient was transferred to the intensive care
unit (ICU) with a severely elevated Aa-gradient of 180.3 mm Hg.
The patient was intubated on day 9 of hospitalization. As permitted
by the clinical trial protocol, intravenous sargramostim was initiated
in addition to broad-spectrum antibiotics, methylprednisolone, prone
ventilation and inhaled nitric oxide, which could only temporarily
improve oxygenation. Ultimately, extracorporeal membrane
oxygenation (ECMO) was started after 15 days of hospitalization.
Given the consistent deterioration, persistent detection of viral
RNA, unremitting fever and underlying B cell defect, treatment with
convalescent plasma was considered. After approval of the local
ethical committee, on day 20 of hospitalization, the patient was
transfused with 460 ml convalescent plasma. The donor was a
healthy 31 year old male who had complete resolution of symptoms
after a confirmed, mild SARS-CoV-2 infection. The transfusion was
well tolerated and no adverse reaction was observed.
Following this treatment, the patient became independent of
ECMO within one day and was successfully weaned from
mechanical ventilation within two days. The SARS-CoV-2–
specific neutralizing antibody titers slightly increased following
the transfusion, but remained low (see Supplementary Table 3).
The patient was transferred from the ICU to the COVID-19
ward on day 26 of hospitalisation, and another 7 days later he
was discharged in good condition. The immunoglobulin
substitution was continued at 12 g per week subcutaneously
and azithromycin thrice weekly was initiated. Viral RNA
remained detectable up to day 60 since symptom onset.
Immunological work-up revealed an impaired, but not
completely abolished humoral response to SARS-CoV-2.
Throughout the disease course SARS-CoV-2 spike S1 protein-
specific IgA and nucleocapsidprotein-specific IgG remained
negative, with a modest increase following the transfusion ofNovember 2020 | Volume 11 | Article 596761
FIGURE 2 | Complete resolution of the pulmonary infiltrates following recovery. (A) Computerized tomography (CT) 2 months before SARS-SoV-2 infection. (B) CT
at hospital admission. (C) CT at hospital discharge. (D) CT at follow-up.
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antibodies reported elsewhere (10). In contrast, a reduced and
delayed SARS-CoV-2 spike S1 protein-specific IgG could be
detected, decreasing again at 25 weeks (see Figure 3A). In
parallel, we studied cellular immune responses. SARS-CoV-2–
specific cytotoxic lymphocytes were low throughout the time
course, which was comparable with the control population. The
patient generated a strong IL-2/IFNg double-positive polyfunctional
CD4+ T cell memory response and a IL-2/IFNg CD8+ T cell
response comparable to a reference population (see Figure 3B).
Finally, we also tested the innate antiviral response and found a
comparable interferon stimulated gene induction upon TLR7 and
recombinant interferon-a (Figure 3C). These results indicated that
the immunodeficiency was restricted to an impaired humoral
response towards SARS-CoV-2.DISCUSSION
Twomain conclusions can be drawn from this case. First, the use of
convalescent plasma might be considered as a therapeutic option in
immunodeficient patients with severe COVID-19. Following the
transfusion of convalescent plasma in this patient with a humoral
immunodeficiency, ongoing fever and persisting detection of viral
RNA, the patient could be weaned from ECMO and mechanical
ventilation within 2 days. Second, a different course in SARS-CoV-2
infection can occur in patients with immunodeficiencies, with
possibly prolonged viral shedding as SARS-CoV-2 RNA could be
detected up to 60 days since symptom onset.
In general, the effect of convalescent plasma can be explained by
two proposed mechanisms of action. First, pathogen-specific
neutralizing antibodies can limit viral amplification by binding the
immunogenic S protein and inhibiting cellular entry (11). In patients
with immunodeficiencies, passive immunization has proven to beFrontiers in Immunology | www.frontiersin.org 3successful in the prevention and treatment of other viral infections,
and this benefit might also be applicable for COVID-19, as illustrated
here. Second, convalescent plasma has broad immunomodulatory
effects, which involve the complement cascade, cytokine regulation,
and other factors (11). Patients with CVID are well known to have
dysregulated immune reactions and therefore immunomodulation
could be beneficial in severe COVID-19.
An important concern for passive immunization is antibody-
dependent enhancement (ADE). Non-neutralizing antibodies can
facilitate viral cellular entry through interaction with Fc receptors
on host cells, which can enhance inflammatory signalling,
facilitate host cell infection, or both (11). ADE has been shown
to occur in vitro in SARS-CoV and MERS-CoV (11, 12). A recent
report also highlights pathogenic roles of antibodies in COVID-19
(13). This might explain why severe disease usually occurs around
day 7 after symptom onset. Other possible concerns for wide-
spread use of convalescent plasma include circulatory overload,
thrombosis, infections and acute lung injury (11, 14).
Despite these theoretical concerns, as of October 2020, the
current literature supports the safety of convalescent plasma (14).
Its effectiveness in COVID-19 still remains to be established, as
adequately powered randomized clinical trials are still lacking
(15). Despite its uncontrolled nature, this case report supports the
beneficial effect of convalescent plasma in patients with humoral
immunodeficiencies and evidence of ongoing viral replication. To
draw firm conclusions on the effect in immunodeficient patients,
data from larger cohorts will be required however.
To date, little is known about the disease course of COVID-19 in
patients with CVID, as conclusions are drawn from case reports
(16). While patients with agammaglobulinemia experienced mild
COVID-19–related symptoms (5, 6), the prolonged ventilation and
extracorporeal support of this and another CVID patient
underscores the heterogeneity of COVID-19 in patients with




FIGURE 3 | Immune Responses to SARS-CoV-2.
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tyrosine kinase (defective in some forms of agammaglobulinemia)
drives FcgR-mediated cytokine production in monocytes (17, 18).
Patients treated with anti-CD20 antibodies, such as rituximab and
ocrelizumab, had equally diverse outcomes and it is still unclear
whether anti-CD20 treatment impacts disease susceptibility or
severity (16). Protracted infectivity should be considered in
immunodeficient patients with SARS-CoV-2 infection. Although
no virus could be cultured from a nasopharyngeal swab taken on day
74, the duration of positive results on polymerase chain reaction
suggest an infectivity longer than described anywhere else.
More data on COVID-19 in immunodeficient patients
are needed. For now, convalescent plasma can be considered a
safe and potentially effective treatment in patients with
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